Delayed initial radioiodine therapy related to incomplete response in low‐ to intermediate‐risk differentiated thyroid cancer

Delayed initial radioiodine therapy related to incomplete response in low‐ to... INTRODUCTIONSelective radioiodine (RAI) therapy contributes to reducing the risk of recurrence and mortality in differentiated thyroid cancer (DTC) patients after thyroidectomy. So far, the optimal time to initiate RAI therapy after surgery remains unclear and no definite recommendations could be found in current relative guidelines. The initiating time of RAI varies worldwide and may be affected by personal, social environmental and disease‐related factors. Whether the initiating time will affect the clinical outcome of RAI treatment remains uncertain. Few clinical studies have focused on this issue with controversial conclusions. Higashi et al reported that delayed RAI therapy (>180 days after total thyroidectomy) may result in poor survival for DTC compared with early RAI therapy. Other authors claimed that the timing of RAI therapy would no impact the overall survival (OS) and disease‐free survival (DFS). It is noteworthy that in these studies, clinical outcome was evaluated in terms of OS and DFS. However, OS is not sufficient or appropriate to evaluate the clinical outcome for all patients with DTC, especially for those low‐ to intermediate‐risk patients, who had an excellent 5‐year OS more than 95%. Recently, a new therapy response system was proposed by the American Thyroid Association guideline (version 2015) (Table ). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Endocrinology Wiley

Delayed initial radioiodine therapy related to incomplete response in low‐ to intermediate‐risk differentiated thyroid cancer

Loading next page...
 
/lp/wiley/delayed-initial-radioiodine-therapy-related-to-incomplete-response-in-SRzgBfZTEQ
Publisher
Wiley
Copyright
Copyright © 2018 John Wiley & Sons Ltd
ISSN
0300-0664
eISSN
1365-2265
D.O.I.
10.1111/cen.13551
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONSelective radioiodine (RAI) therapy contributes to reducing the risk of recurrence and mortality in differentiated thyroid cancer (DTC) patients after thyroidectomy. So far, the optimal time to initiate RAI therapy after surgery remains unclear and no definite recommendations could be found in current relative guidelines. The initiating time of RAI varies worldwide and may be affected by personal, social environmental and disease‐related factors. Whether the initiating time will affect the clinical outcome of RAI treatment remains uncertain. Few clinical studies have focused on this issue with controversial conclusions. Higashi et al reported that delayed RAI therapy (>180 days after total thyroidectomy) may result in poor survival for DTC compared with early RAI therapy. Other authors claimed that the timing of RAI therapy would no impact the overall survival (OS) and disease‐free survival (DFS). It is noteworthy that in these studies, clinical outcome was evaluated in terms of OS and DFS. However, OS is not sufficient or appropriate to evaluate the clinical outcome for all patients with DTC, especially for those low‐ to intermediate‐risk patients, who had an excellent 5‐year OS more than 95%. Recently, a new therapy response system was proposed by the American Thyroid Association guideline (version 2015) (Table ).

Journal

Clinical EndocrinologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off